Cargando…
A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol
BACKGROUND: Cardiovascular complications are the leading cause of mortality and morbidity in Marfan syndrome (MFS), a dominantly inherited disorder caused by mutations in the gene that encodes fibrillin-1. There are approximately 18,000 patients in the UK with MFS. Current treatment includes careful...
Autores principales: | Mullen, Michael J, Flather, Marcus D, Jin, Xu Yu, Newman, William G, Erdem, Guliz, Gaze, David, Valencia, Oswaldo, Banya, Winston, Foley, Claire E, Child, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220813/ https://www.ncbi.nlm.nih.gov/pubmed/24289736 http://dx.doi.org/10.1186/1745-6215-14-408 |
Ejemplares similares
-
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
por: Mullen, Michael, et al.
Publicado: (2019) -
Exaggerated elastin turnover in young individuals with Marfan syndrome: new insights from the AIMS trial
por: Iskandar, Zaid, et al.
Publicado: (2023) -
New Screening Tool for Aortic Root Dilation in Children with Marfan Syndrome and Marfan-Like Disorders
por: Wozniak-Mielczarek, Lidia, et al.
Publicado: (2020) -
Pectus updates and special considerations in Marfan syndrome
por: Fraser, Stephanie, et al.
Publicado: (2018) -
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration
por: Pitcher, Alex, et al.
Publicado: (2015)